Skip to main content

Leptomeningeal Disease clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

    open to eligible people ages 18 years and up

    A phase 2 non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in HER2-neu positive breast cancer.

    San Francisco, California and other locations

Last updated: